177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term …

…, M Ocak, OE Sahin, N Alan-Selcuk… - Nuclear medicine …, 2018 - journals.lww.com
Purpose Upon diagnosis, distant metastases are encountered in 21–50% of neuroendocrine
tumours (NETs). However, few systemic treatment options are available for the well-…

Clinical Experience with [225Ac] Ac-PSMA Treatment in Patients with [177Lu] Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer

N Alan-Selcuk, G Beydagi, E Demirci… - Journal of Nuclear …, 2023 - Soc Nuclear Med
For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC)
who do not respond to [ 177 Lu]Lu-PSMA therapy, there are limited treatment options. Clinical …

Radiolabeled FAP inhibitors as new pantumoral radiopharmaceuticals for PET imaging: a pictorial essay

…, E Demirci, P Castellucci, N Alan-Selçuk… - Clinical and …, 2023 - Springer
Fibroblast activation protein (FAP)-targeted radiopharmaceuticals recently emerged as
potential pantumoral agent for PET imaging. FAPi PET provides the opportunity to explore the …

Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria

…, R Akyel, B Caner, N Alan-Selçuk… - Nuclear medicine …, 2020 - journals.lww.com
Aim In this study, we aimed to measure interobserver and intraobserver agreement in Ga-68–prostate-specific
membrane antigen (PSMA) PET/computed tomography (CT) image …

Evaluation of the dosimetry approaches in ablation treatment of thyroid cancer

N Alan Selcuk, T Toklu, S Beykan… - Journal of Applied …, 2018 - Wiley Online Library
In this study, we aimed to evaluate dosimetric approaches in ablation treatment of Differentiated
Thyroid Carcinoma ( DTC ) without interrupting the clinical routine. Prior to therapy, 10.7 …

Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases

L Kabasakal, NA Selçuk, H Shafipour, O Ozmen… - European journal of …, 2004 - Springer
Purpose During the follow-up of patients with well-differentiated thyroid carcinoma, some
patients have elevated serum thyroglobulin (Tg) levels without any evidence of radioiodine …

Prediction of clinically significant prostate cancer by [68 Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance

…, S Asa, F Aghazada, T Toklu, NA Selcuk… - European Journal of …, 2024 - Springer
Purpose In our study, our aim was to investigate the role of [ 68 Ga]Ga-PSMA-11 PET /CT
imaging in the diagnosis of clinically significant prostate cancer (csPCa) (ISUP GG 2 and higher…

[HTML][HTML] Initial Findings on the Use of [225Ac] Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors

E Demirci, NA Selçuk, G Beydağı, M Ocak… - Molecular Imaging …, 2023 - ncbi.nlm.nih.gov
Objectives: This study aimed to evaluate the stability, safety, and efficacy of alpha-targeted
therapy with [225 Ac] Ac-DOTATATE in patients with grade 1/2 metastatic neuroendocrine …

[68Ga]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach

N Alan-Selçuk, S Ergen, E Demirci, M Ocak… - European Journal of …, 2021 - Springer
Approximately 18 months after the resection of a gastric singet ring cell carcinoma (T3N3bM0)
a 56-year-old male presented due to increasing exertional dyspnea. Bilateral massive …

ESTIMATION OF THE ORGAN ABSORBED DOSES AND EFFECTIVE DOSE FROM 68Ga-PSMA-11 PET SCAN

…, N Yeyin, M Ocak, N Alan-Selcuk… - Radiation protection …, 2018 - academic.oup.com
68 Ga-PSMA-11 PET/CT has been proven to have high clinical value for imaging of prostate
cancer and rapidly gained popularity. In this study, we aimed to investigate absorbed doses …